A Calquence win seven years in the making
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
Adicet pivots
After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.
Lilly makes steady progress in non-covalent BTK inhibition
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
